BioTuesdays

Tag - ELND005

Feature

AD focus shifts to treating agitation/aggression

By Len Zehr After years of fruitless search for new therapies to slow the deadly progression of Alzheimer’s disease (AD), researchers are having more success with experimental treatments for the neuropsychiatric...

October 28, 2014
Feature

Transition moves into late-stage drug development

By Len Zehr Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate, ELND005...

March 18, 2014